摘要:
Die Erfindung betrifft ein Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions, wobei in einer ersten Stufe ein primäres aliphatisches Amin R-NH 2 mit Trifluormethansulfonsäureanhydrid Tf 2 O zum entsprechenden N-alkylierten Trifluormethansulfonsäureimid R-NTf 2 umgesetzt wird, das in einer zweiten Stufe mit einem Nukleophil Nu zu einer ionischen Flüssigkeit, bestehend aus dem entsprechenden alkylierten Nukleophil R-Nu + als Kation und dem Bistriflimid-Anion Tf 2 N - weiter umgesetzt wird: (I) dadurch gekennzeichnet, dass a) in der ersten Stufe ein in einem organischen Lösungsmittel gelöstes Alkylamin mit zumindest 3 Kohlenstoffatomen eingesetzt wird; b) in der zweiten Stufe ein Stickstoff-Heterozyklus oder eine Phosphorverbindung als Nukleophil eingesetzt wird; und c) beide Stufen in einem kontinuierlichen Fluss durchgeführt werden.
摘要:
The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
摘要:
The present invention provides a crystalline form R of tedizolid phosphate, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of bacterial infections.
摘要:
The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.
摘要:
The present invention provides novel Ruthenium-based transition metal complex catalysts comprising specific ligands, their preparation and their use in hydrogenation processes. Such complex catalysts are inexpensive, thermally robust, and olefin selective.
摘要:
A process for preparing azomethines of the general formula (V) where R is an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted alkyl radical or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms, and R 1 is an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms, R 2 is hydrogen or an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted alkyl radical or an optionally substituted cycloalkyl radical or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms by reacting alpha-oxo carboxylates of the general formula (I) where n is a number in the range from 1 to 6, M (n+) is a cation, with aryl bromides of the general formula (IV) and amines of the general formula (II) via the alpha-iminocarboxylate intermediate of the general formula (III), in the presence of two transition metals or compounds thereof as catalyst, is described.